60 results about "Liver necrosis" patented technology

The invention discloses a composite fungal intercellular polysaccharide composition with a liver protecting function and a preparation method. The composite fungal intercellular polysaccharide composition comprises 10-45 weight parts of coprinus comatus intercellular polysaccharide, 20-50 weight parts of white fungus intercellular polysaccharide and 20-45 weight parts of hohenbuehelia serotina intercellular polysaccharide. The preparation method comprises the steps of fermenting fungi, crushing the separated mycelia, adding enzyme for reacting, and separating solid and liquid phases; adding distilled water into the solid phase, then performing ultrasonic treatment, adding ethanol liquid, collecting and drying the sediment; concentrating the liquid phase, adding ethanol, standing, centrifuging to separate the sediment; combining the sediments obtained by solid and liquid phase treatment to obtain homogenous intercellular polysaccharides; and mixing the coprinus comatus intercellular polysaccharide, the white fungus intercellular polysaccharide and the hohenbuehelia serotina intercellular polysaccharide obtained by the method respectively to obtain the composite fungal intercellular polysaccharide composition with the liver protecting function. The composition has the advantages of effectively reducing the ALT (alanine aminotransferase) and AST (aspartate aminotransferase) level of serum, obviously reducing the malonaldehyde content of injured liver and obviously promoting biliary excretion so that the function of the injured liver can be recovered.

The invention discloses application of schisandrol B in preparation of a medicine for preventing and treating cholestatic liver disease. By giving an excess amount of lithocholic acid, a mice intrahepatic cholestasis model is made, or a mice extrahepatic cholestasis model is made by bile duct ligation, then the mice intrahepatic cholestasis model and the mice extrahepatic cholestasis model are respectively collaboratively given the schisandrol, liver injury can be effectively alleviated, the bile acid level is reduced, glutamic-pyruvic transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activity are decreased significantly, liver tissue necrosis degree is significantly alleviated, at the same time, total bile acid and total bilirubin content in serum are significantly reduced, and the total bile acid and total bilirubin content discharged with urine are increased. The results show that the schisandrol B can prevent and treat cholestatic liver injury induced by lithocholic acid and bile duct ligation, and prove that the effect mechanism may be involved in regulation of CYP3A11, UGT1A1 and OATP1A4 mediated bile acid metabolism and excretion.

The invention is applicable to the technical field of medical treatment, and provides an organ preservation solution and a liver in-vitro preservation method, the organ preservation solution comprises the following components: a UW solution and resveratrol; the combined use of the resveratrol and the UW liquid can reduce liver enzymatic injury markers and improve the liver tissue form, which indicates that the combined use of the resveratrol and the UW liquid can effectively improve the donor liver quality and reduce the donor liver injury; particularly, a remarkable protection effect is achieved in static cold preservation of liver transplantation donor liver; and the problems that an existing organ preserving fluid is difficult to repair the liver of a donor, but due to the limited preserving effect of the organ preserving fluid, many marginal donor livers completely fall into waste livers after a traditional preserving mode is applied, and a large number of precious liver sources are wasted are solved.

The invention discloses a recombined Q-typed hPON1Q in the biological pharmaceutical technological domain, which is characterized by the following: transmitting expressive plasmid to do ectopic secretory expression through skeletal muscle excited by electricity; improving serum PON1 level effectively; preventing liver from damaging as new gene drug; maintaining the activity of phosphoroso enzyme over 16d; making the genome-switching mouse serum ALT and AST level lower than positive contrast group (P<0.01).

The invention relates to the use of Fraxinellone as medicament for treating hepatic diseases, wherein the Fraxinellone is separated from the velamen of Dictamnus dasycorpus Turcz, the Fraxinellone can substantially improve acute hepatic injury in mouse induced with CCl4, D-galactosamine and lipopolysaccharide, in addition, the Fraxinellone can substantially inhibit the release of glutamate-pyruvate transaminase in CCl4 induced mouse primary culture hepatocytes injuries, thus can be used as a novel medicament for treating hepatic diseases.

The invention relates to the technical field of medicines, in particular to a drug for preventing and controlling fulminant hepatitis. Research shows the expression of the liver tissue A20 can be regulated up greatly by the NOD1 receptor agonist; the A20 (also called TNFAIP3) refers to anti-inflammatory signaling molecule, and can achieve anti-apoptosis action by lowering NF-kB signal channel, soas to protect the liver cells. Besides, the NOD1 receptor agonist can decrease the serum ALT level and the liver tissue cl-caspase3 level of mice with fulminant hepatitis greatly, thereby reducing liver injury of the mice with fulminant hepatitis and decreasing apoptosis of the liver cells. The conclusion is the NOD1 receptor agonist can be applied to treating fulminant hepatitis.

The invention discloses an application of a schisandra chinensis monomer compound in preparation of drugs for prevention and treatment of hepatotoxicity caused by acetaminophen (APAP), wherein the schisandra chinensis monomer compound is deoxyschizandrin, schisandrin C, schisandrin or schisantherin a. Experiment results show that: with the schisandra chinensis monomer compound, the ALT content and the AST content in the APAP-induced liver injury animal model can be significantly reduced, consumption of glutathione in liver cells can be inhibited, the liver cell necrosis degree can be effectively improved, and the schisandra chinensis monomer compound provides significant treatment and protection effects for hepatotoxicity symptoms caused by APAP.

The invention relates to novel application of structure modified products of salvianolic acid B in pharmacy. The structure modified products of the salvianolic acid B can obviously inhibit the rise of CK and LDH in blood serum, obviously reduce MDA level and improve SOD activity, has effects of resisting oxidation and removing oxygen radical, can improve the condition of myocardial ischemia to obviously relieve the illness state of miocardial infarction, can obviously prolong the time for forming thrombus, and can be applied in preparing medicaments for resisting the myocardial ischemia, medicaments for protecting myocardial ischemia-reperfusion cardiac microvascular endothelial cells, medicaments for resisting cerebral ischemia, medicaments for resisting atherosclerosis, medicaments for resisting the thrombus, anti-ageing medicaments, antitumor medicaments, and medicaments for resisting liver injury and liver fibrosis. The novel application has the advantage that: the application range of the structure modified products of the salvianolic acid B in pharmacy is determined, so that the preparation of the novel medicaments of which the pharmacological activity and bioavailability are higher than those of the salvianolic acid B is possible.

The invention discloses an oplopanaxelatusNakai chlorogenic acid extract and a preparation method and application thereof. The method comprises the steps that an adventitious root material of oplopanaxelatusNakai is obtained by combining a tissue culture means and utilizing a bioreactor, and the chlorogenic acid extract of oplopanaxelatusNakai is obtained through macroporous adsorption resin extraction and separation. The adventitious root chlorogenic acid extract of oplopanaxelatusNakai can significantly protect liver injury caused by acetaminophen, the liver necrosis degree is obviously reduced, the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase can be significantly reduced, mitochondrial oxidative stress reaction caused by liver injury caused by excessive acetaminophen can be reduced, the activity of superoxide dismutase, catalase and glutathione in the liver is obviously restored, the content of malondialdehyde is reduced, the drug metabolism of acetaminophen in the liver is affected, and therefore the aseptic inflammatory injury of neutral granulocytes to the liver is reduced, the liver is protected, and liver injury is reduced.

The invention relates to the technical field of medicine, in particular to the use of rhein in the preparation of drugs for prevention and treatment of hepatic encephalopathy. The application of rheinin the preparation of drugs for preventing and treating hepatic encephalopathy is disclosed for the first time. The model of hepatic encephalopathy induced by thioacetamide (TAA) and carbon tetrachloride (CCL4) was tested repeatedly. The results showed that rhein could reduce blood ammonia, alleviate inflammation of liver and brain tissue, protect liver function, reduce liver necrosis and improveliver injury and brain injury. Therefore, rhein or its salts can be used to prepare drugs for the prevention and treatment of hepatic encephalopathy. Rhein or its salts can be used as active ingredients to prevent and cure hepatic encephalopathy, which has the advantages of obvious effect, less dosage and quick onset.

The invention discloses a method for constructing a liver and immune double-humanized large animal model by utilizing single stem cell transplantation. The method comprises the following steps: acquiring human stem cells, transplanting a single stem cell into a large animal with liver injury, embedding human liver cells, forming a humanized immune system, and the like. The method can be used for researching the pathogenesis of human body diseases and researching, developing and screening new clinical medicines, and also can be used for obtaining an infectious disease model, a liver disease and drug metabolism model, a tumor growth and cancer immune model, an organ transplantation model, an autogenous immune disease model and the like which more accord with the development history of human diseases; and the humanized model which is convenient, simple, easy to obtain and high in similarity with a human body is provided for clinical liver disease treatment research.

The invention relates to the field of biomedicine, and provides a Kupffer cell activity inhibitor. The activity inhibitor is a recombinant human IL-1 receptor antagonist (rhIL-1Ra). Experiments find that the rhIL-1Ra significantly inhibits the activity of large Kupffer cells with high expression of IL-1RI, and inhibits the ultrastructure and phagocytic activity of Kupffer cells, thereby inhibitingthe activity of the Kupffer cells, significantly reducing hepatocyte apoptosis and promoting liver cell proliferation. According to the above conclusions, the recombinant human IL-1 receptor antagonist (rhIL-1Ra) reduces the hepatocyte apoptosis and promotes hepatocyte regeneration by inhibiting the activity of the Kupffer cells, and provides a strategy for preparing a drug for treating acute liver failure and liver injury.

Disclosed is a non-invasive method for assessing the presence and/or severity of varices selected from gastric and esophageal varices in a liver disease patient, wherein the method includes: (a) carrying out one or more non-invasive test(s) for assessing the severity of a hepatic lesion or disorder, wherein the non-invasive test(s) each result in a value; and (b) comparing the value(s) obtained at step (a) with cut-offs of the non-invasive test(s) for assessing the presence and/or severity of varices selected from gastric and esophageal varices.

The invention discloses application of L-malic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury, and particularly discloses application of the L-malic acid serving as a unique active ingredient in preparation of a medicine or a health care product for preventing or treating the liver ischemia-reperfusion injury. Mouse in-vivo experiments prove that the L-malate can significantly reduce the increase of hepatic injury markers such as alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase in serum caused by hepatic ischemia/reperfusion, and reduce the hepatic necrosis area; and meanwhile, liver tissue lipid peroxidation and cell ferroptosis caused by ischemia/reperfusion are inhibited, so that hepatic injury is relieved. The invention provides a theoretical basis for treatment of hepatic ischemia/reperfusion injury related diseases, and has clinical application value.

The invention discloses construction and application of a multi-cell co-cultured three-dimensional liver microsphere model, and belongs to the technical field of cell microspheres. The construction method of the multi-cell co-culture three-dimensional model comprises the following steps: preparing a mixed cell suspension from parenchymal hepatic cells, hepatic stellate cells and endothelial cells; and adding the mixed cell suspension into an ultralow adsorption pore plate, and performing culturing for 1-2 days to obtain the multi-cell co-culture three-dimensional model, wherein the number ratio of parenchymal hepatic cells to hepatic stellate cells to endothelial cells in the mixed cell suspension is 4: 1: 1, the parenchymal hepatic cell is a human liver cancer cell HepG2, the hepatic stellate cell is LX-2, and the endothelial cell is a human umbilical vein fusion cell EA.hy926. The model disclosed by the invention can be in omnibearing contact with a culture solution and other cells, and is closer to a cell environment in a human body, so that the evaluation of the three-dimensional model on hepatotoxicity or liver injury is more accurate and reliable.

The invention discloses application of an MMI-0100 oligopeptide compound in preparation of a medicine for treating cholestatic liver diseases. The amino acid sequence of the MMI-0100 oligopeptide compound is as follows: YARAAARQARAKALARQLGVAA. After MMI-0100 drug treatment, the fibrosis lesion of the mouse liver is relieved, the infiltration of inflammatory cells is reduced, meanwhile, the hyperplasia degree of the bile duct is relieved, the mRNA expression level of the liver fibrosis gene alpha-SMA is reduced, and the results show that the MMI-0100 has a good treatment effect on the cholestatic liver injury.